Moreover, the International Association of the Study of Lung Cancer (IASCLC) consensus statement in 2021 concluded that plasma ctDNA approaches have significant potential to improve patient care, and immediate implementation in the clinic is justified in a number of therapeutic settings in NSCLC, including in the diagnosis of EGFR kinase inhibitor resistance (EGFR T790M) [6]. The gene discussed is EGFR; the disease is lung carcinoma.